Thymosin Alpha-1 is a 28-amino-acid immunomodulator. Mechanism, the Zadaxin regulatory record, orphan designations, and what the evidence actually supports. RUO.
Thymosin Alpha-1 sits in an unusual spot in the founder-operator stack. It's an RUO purchase in the US. It's an approved drug in roughly thirty other countries under the brand Zadaxin. The Western literature is real and indexed and includes infectious disease and oncology endpoints — meaningfully different from the Russian-corpus situation around Selank, Semax, and Epitalon. This page is mechanism through corpus before you read anyone's stack take.
For research use only. Not medical advice. Nothing here is a recommendation to administer, prescribe, or self-administer any compound.
Thymosin Alpha-1. A synthetic 28-amino-acid peptide identical to the Thymosin Alpha-1 sequence originally isolated from Thymosin Fraction 5, a thymic peptide preparation characterized by Allan Goldstein and colleagues at the Albert Einstein College of Medicine, beginning in the 1970s.
Mechanism class: immunomodulator. Brand name when approved as a pharmaceutical: Zadaxin (generic: thymalfasin). Approved as a prescription drug in roughly thirty countries — including across Asia, parts of Europe, and parts of Latin America — primarily for chronic hepatitis B and C and as an adjunct in certain oncology and immunocompromised contexts. Not approved in the US. Holds orphan drug designations from the FDA for several indications, which is a regulatory recognition of the molecule and the disease target without amounting to approval.
The category Thymosin Alpha-1 lives in inside this newsletter: immune-axis research peptides.
Thymosin Alpha-1 is a thymus-derived signaling peptide. The thymus is the organ where T-cells mature; the published mechanism work centers on what TA1 does to that maturation pipeline and the broader innate–adaptive immune handoff.
The published mechanism story clusters in four areas.
T-cell maturation and differentiation. TA1 has effects on thymocyte maturation in animal and in-vitro models, with downstream changes in CD4/CD8 ratios and T-cell function in some clinical contexts. This is the foundational mechanism story going back to the Goldstein program.
Toll-like receptor signaling. Later mechanism work — substantially driven by Enrico Garaci and colleagues in Italy — characterizes TA1 as a modulator of TLR signaling, particularly TLR9 and the dendritic-cell axis. This part of the mechanism story bridges innate immunity to the T-cell story.
Cytokine modulation. Effects on IL-2, interferon-gamma, and other cytokines in clinical immunocompromised populations.
Adjuvant effects with vaccines and antiviral therapy. The clinical use case for Zadaxin in chronic hepatitis was as an immunomodulator paired with antiviral drugs, with response-rate endpoints as the primary measure.
The one-line summary the literature supports: a thymic-derived immunomodulator with characterized effects on T-cell maturation, TLR signaling, and clinical immune endpoints in the populations studied.
The one-line summary the literature does not support: a settled "general immune booster" claim for healthy founder-operators, which is not a population the registration trials targeted.
Half-life. Approximately 2 hours in humans for the parent peptide. Short relative to long-acting peptide drugs, which is part of why the registered Zadaxin protocol uses repeated subcutaneous administration on a defined schedule rather than once-weekly dosing.
Route. Subcutaneous injection is the dominant administered route across the Zadaxin clinical corpus and across the founder-operator field reports. Intranasal preparations exist in some research contexts; oral administration is not characterized — the peptide is digested.
This is where Thymosin Alpha-1 looks meaningfully different from the Russian-corpus peptides on the rest of this page set.
The TA1 literature is substantial, English-language, and indexed. PubMed has hundreds of papers spanning preclinical immunology, mechanism, and clinical endpoints. Foundational authors: Goldstein, Garaci, Romani, Tuthill. The Zadaxin clinical-trial corpus exists in the regulatory record of the countries where the drug is approved.
What's actually in the corpus:
Regulatory record matters here as a literature signal:
In the tier framework:
The honest framing: Thymosin Alpha-1 has a deeper, English-indexed Western evidence base than most peptides in the founder stack. It's also true that the founder-operator use case (general immune support in healthy adults) is not what the trial corpus studied.
Field reports cluster in three areas.
Cold and respiratory frequency. The most common reported subjective change among healthy users: a perceived reduction in upper-respiratory illness frequency or duration over a multi-month cycle. This is consistent with the immunomodulator framing but not a trial-grade endpoint.
Recovery-during-illness reports. Users who initiated TA1 during acute viral illness sometimes report subjective faster recovery. The COVID-era clinical work on TA1 in severe illness has shaped how some founders frame this; the founder-cohort use case is not equivalent to the ICU populations studied.
Stack pairing. Most often paired with BPC-157 or TB-500 in the recovery-and-resilience cluster, or with Epitalon in the longevity cluster. TA1 fits both depending on the operator's read.
None of this is a recommendation. Founder N=1 reports are signal, not proof.
If anyone tells you TA1 is the "proven immune peptide for healthy users," they're skipping the part where the proof is in patient populations and the founder use case is an extrapolation.
Thymosin Alpha-1 is one of the immune-axis compounds covered in The 2026 Peptide Stack Map — the lead magnet at the link below. Mechanism, half-life, literature, gaps. Issue 1 is the entry point.
The Sunday issues cover TA1 in the immune-and-recovery cluster alongside BPC-157, TB-500, and the broader regulatory-record peptides. The dose-citation work — what doses appear in the published Zadaxin protocols and the sepsis trials — lives behind the email gate, where it belongs.
Subscribe for the weekly briefing on what's new, what survived peer review, and what's worth the vial.
Disclosure: The operator who publishes The Compound also owns heroxbio.com, an RUO peptide vendor. Full FTC disclosure on the About page. For research use only. Not medical advice. Nothing on this page is a recommendation to administer, prescribe, or self-administer any compound.
Subscribe to The Compound — the Sunday briefing on peptides for founder-operators. One email a week. Pull down the Stack Map on signup.
14 compounds, half-lives, and the literature — one PDF.
Download the PDF →